Please Wait.....
Report
Europe Branded Generics Market
Market Report I 2025-11-01 I 350 Pages I Data Bridge Market Research
Europe branded generics market is expected to reach USD 96.48 billion by 2032 from USD 67.96 billion in 2024, growing at a substantial CAGR of 4.5% in the forecast period of 2025 to 2032.
Market Segmentation:
Europe Branded Generics Market, By Drug Class (Anti-Hypertensive, Hormones, Antimetabolites, Lipid Lowering Drugs, Anti-Epileptics, Alkylating Agents, Anti-Depressants, Anti-Psychotics, Others), Application (Cardiovascular Diseases, Pain Management and Anti-inflammatory, Oncology, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology, Others), Route of Administration (Oral, Injectable, Topical Administration, Others), Product Type (Value-Added Branded Generics, Trade Named Generics), Patient Demographics (Adult, Geriatric, Pediatric), End User (Hospitals, Clinics, Homecare, Academic & Research Institutes, Others) Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Direct Tenders, Others) Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest Of Europe).
Overview of the Europe Branded generics Market are:
Driver
- Patent expirations of blockbuster drugs
- Rising prevalence of chronic diseases
- Cost-effective alternative to innovator drugs
- Simplified approval pathways for branded generics
Restrain
- Patent litigation and intellectual property risks
- Counterfeit and substandard drugs
Opportunity
- Expansion of branded generic drug in emerging markets
- Patent cliff of major drugs
- Expansion into specialty and complex generics
Market Players:
The key market players for Europe branded generics market are listed below:
- Teva Pharmaceutical Industries Ltd. (Israel)
- Viatris Inc. (U.S.)
- Sandoz Group AG (Switzerland)
- Dr. Reddy's Laboratories Ltd. (India)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Cipla Pharmaceuticals (India)
- Fresenius Kabi (Germany)
- Abbott (U.S.)
- Glenmark Pharmaceuticals (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Lupin Pharmaceuticals (India)
- Emcure Pharmaceuticals (India)
- Bausch Health Companies Inc. (Canada)
- Mankind Pharma (India)
- Jubilant Pharma (India)
- Natco Pharma (India)
- ARISTO Pharmaceuticals Private Limited (India)
- Biocon Limited (India)
- Torrent Pharmaceuticals Ltd. (India)
- Endo, Inc. (U.S.)
- Alembic Pharmaceuticals Limited (India)
- SAGENT Pharmaceuticals (U.S.)
- Panacea Biotec (India)
TABLE OF CONTENTS
1 INTRODUCTION 196
1.1 OBJECTIVES OF THE STUDY 196
1.2 MARKET DEFINITION 196
1.3 OVERVIEW OF EUROPE BRANDED GENERICS MARKET 196
1.4 LIMITATIONS 199
1.5 MARKETS COVERED 200
2 MARKET SEGMENTATION 208
2.1 MARKETS COVERED 208
2.2 GEOGRAPHICAL SCOPE 209
2.3 YEARS CONSIDERED FOR THE STUDY 210
2.4 CURRENCY AND PRICING 210
2.5 DBMR TRIPOD DATA VALIDATION MODEL 211
2.6 MULTIVARIATE MODELLING 214
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 215
2.8 DBMR MARKET POSITION GRID 217
2.9 MARKET END USER COVERAGE GRID 218
2.10 SECONDARY SOURCES 219
2.11 ASSUMPTIONS 220
3 EXECUTIVE SUMMARY 221
4 PREMIUM INSIGHTS 228
4.1 PORTER'S FIVE FORCES ANALYSIS 229
4.2 BRAND OUTLOOK 230
4.2.1 PRODUCT VS BRAND OVERVIEW 231
4.2.1.1 PRODUCT OVERVIEW 231
4.2.1.2 BRAND OVERVIEW 232
4.3 CONSUMER BUYING BEHAVIOUR - EUROPE BRANDED GENERICS MARKET 233
4.4 INNOVATION TRACKER AND STRATEGIC ANALYSIS 235
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS 235
4.4.1.1 JOINT VENTURES 235
4.4.1.2 MERGERS AND ACQUISITIONS 235
4.4.1.3 LICENSING AND PARTNERSHIP 236
4.4.1.4 TECHNOLOGY COLLABORATIONS 237
4.4.1.5 STRATEGIC DIVESTMENTS 237
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT 238
4.4.3 STAGE OF DEVELOPMENT 238
4.4.4 TIMELINES AND MILESTONES 238
4.4.5 INNOVATION STRATEGIES AND METHODOLOGIES 238
4.4.6 RISK ASSESSMENT AND MITIGATION 239
4.4.7 FUTURE OUTLOOK 239
4.5 PATENT ANALYSIS - EUROPE BRANDED GENERICS MARKET 240
4.5.1 PATENT QUALITY AND STRENGTH 240
4.5.2 PATENT FAMILIES 240
4.5.3 LICENSING AND COLLABORATIONS 241
4.5.4 REGIONAL PATENT LANDSCAPE 241
4.5.5 IP STRATEGY AND MANAGEMENT 242
4.6 PRICING ANALYSIS 243
4.7 VALUE CHAIN ANALYSIS 245
4.7.1 OVERVIEW 245
4.7.2 RAW MATERIAL SUPPLY 245
4.7.3 COMPONENT MANUFACTURING AND PROCESSING 245
4.7.4 EQUIPMENT AND TECHNOLOGY PROVIDERS 246
4.7.5 DISTRIBUTION AND LOGISTICS 246
4.7.6 END-USERS (BRANDS & INDUSTRY SECTORS) 246
4.7.7 CONCLUSION 247
5 REGULATION COVERAGE 248
5.1 REGULATION COVERAGE (NORTH AMERICA) 248
5.2 REGULATION COVERAGE (SOUTH AMERICA) 251
5.3 REGULATION COVERAGE (EUROPE) 254
5.4 REGULATION COVERAGE (MIDDLE EAST & AFRICA) 257
5.5 REGULATION COVERAGE (ASIA-PACIFIC) 260
5.6 SUPPLY CHAIN ANALYSIS OF EUROPE BRANDED GENERICS MARKET 263
5.6.1 OVERVIEW 263
5.6.2 LOGISTIC COST SCENARIO 263
5.6.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 263
5.6.4 CONCLUSION 263
5.7 TECHNOLOGICAL ADVANCEMENTS- EUROPE BRANDED GENERICS MARKET 264
5.7.1 ADVANCED FORMULATION TECHNOLOGIES 264
5.7.2 CONTINUOUS MANUFACTURING AND PROCESS OPTIMIZATION 264
5.7.3 ANTI-COUNTERFEITING AND SMART PACKAGING TECHNOLOGIES 264
5.7.4 MODIFIED DRUG DELIVERY SYSTEMS 265
5.7.5 DIGITAL TRANSFORMATION AND E-PRESCRIPTION INTEGRATION 265
5.7.6 ADVANCED ANALYTICAL AND QUALITY ASSURANCE TOOLS 265
5.7.7 PERSONALIZED GENERIC THERAPY DEVELOPMENT 265
5.7.8 SUSTAINABILITY AND ECO-FRIENDLY MANUFACTURING 266
6 MARKET OVERVIEW 267
6.1 DRIVERS 269
6.1.1 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS 269
6.1.2 RISING PREVALENCE OF CHRONIC DISEASES 270
6.1.3 COST-EFFECTIVE ALTERNATIVE TO INNOVATOR DRUGS 271
6.1.4 SIMPLIFIED APPROVAL PATHWAYS FOR BRANDED GENERICS 272
6.2 RESTRAINS 273
6.2.1 PATENT LITIGATION AND INTELLECTUAL PROPERTY RISKS 273
6.2.2 COUNTERFEIT AND SUBSTANDARD DRUGS 274
6.3 OPPORTUNITIES 275
6.3.1 EXPANSION OF BRANDED GENERIC DRUG IN EMERGING MARKETS 275
6.3.2 PATENT CLIFF OF MAJOR DRUGS 276
6.3.3 EXPANSION INTO SPECIALTY AND COMPLEX GENERICS 277
6.4 CHALLENGES 278
6.4.1 INTENSE PRICE PRESSURE AMONG COMPETITORS 278
6.4.2 QUALITY PERCEPTION & PHYSICIAN/PATIENT TRUST IN BRANDED GENERIC DRUG 279
7 EUROPE BRANDED GENERIC MARKET, BY DRUG CLASS 280
7.1 OVERVIEW 281
7.2 ANTI-HYPERTENSIVE 284
7.2.1 DIURETICS 286
7.2.2 CE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) 286
7.2.3 ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) 287
7.2.4 BETA BLOCKERS (BBS) 287
7.2.5 CALCIUM CHANNEL BLOCKERS (CCBS) 288
7.2.6 DIRECT VASODILATORS 288
7.2.7 ALPHA-1 BLOCKERS 289
7.2.8 CENTRAL ALPHA-2 AGONISTS 289
7.2.9 HORMONES 290
7.2.10 STEROID HORMONES 291
7.2.11 SEX HORMONES 291
7.2.12 ESTROGENS 292
7.2.13 PROGESTOGENS 292
7.2.14 ANDROGENS 293
7.2.15 THYROID HORMONES 293
7.2.16 OTHER HORMONES 294
7.3 ANTIMETABOLITES 294
7.3.1 PURINE ANALOGUES 295
7.3.2 PYRIMIDINE ANALOGUES 296
7.3.3 FOLATE ANTAGONISTS 296
7.4 LIPID LOWERING DRUGS 297
7.4.1 STATINS (HMG-COA REDUCTASE INHIBITORS) 298
7.4.2 COMBINATION PRODUCTS AND OTHER AGENTS 299
7.4.3 FIBRATES 299
7.4.4 BILE ACID SEQUESTRANTS 300
7.4.5 PCSK9 INHIBITORS 300
7.5 ANTI-EPILEPTICS 301
7.6 ALKYLATING AGENTS 302
7.6.1 NITROGEN MUSTARDS 304
7.6.2 NITROSOUREAS 304
7.6.3 ALKYL SULFONATES 305
7.6.4 TRIAZENES 305
7.6.5 ETHYLENIMINES 306
7.7 ANTI-DEPRESSANTS 306
7.7.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) 308
7.7.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) 309
7.7.3 TRICYCLIC ANTIDEPRESSANTS (TCAS) 310
7.7.4 ATYPICAL ANTIDEPRESSANTS 311
7.7.5 MONOAMINE OXIDASE INHIBITORS (MAOIS) 311
7.7.6 NMDA RECEPTOR ANTAGONISTS 312
7.8 ANTI-PSYCHOTICS 312
7.8.1 SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS 314
7.8.2 FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS 315
7.8.3 PHENOTHIAZINES 316
7.8.4 THIOXANTHENES 316
7.8.5 NEXT-GENERATION ANTIPSYCHOTICS 317
7.9 OTHERS 317
8 EUROPE BRANDED GENERICS MARKET, BY APPLICATION 318
8.1 OVERVIEW 319
8.2 CARDIOVASCULAR DISEASES 322
8.3 PAIN MANAGEMENT AND ANTI-INFLAMMATORY 323
8.4 ONCOLOGY 324
8.5 DIABETES 326
8.6 NEUROLOGY 327
8.7 GASTROINTESTINAL DISEASES 328
8.8 DERMATOLOGY 329
8.9 OTHERS 330
9 EUROPE BRANDED GENERIC MARKET, BY ROUTE OF ADMINISTRATION 332
9.1 OVERVIEW 333
9.2 ORAL 336
9.3 INJECTABLEA 337
9.4 TOPICAL ADMINISTRATION 338
9.5 OTHERS 340
10 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE 341
10.1 OVERVIEW 342
10.2 VALUE-ADDED BRANDED GENERICS 345
10.3 TRADE NAMED GENERICS 346
11 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS 347
11.1 OVERVIEW 348
11.2 ADULT 351
11.3 GERIATRIC 352
11.4 PEDIATRIC 353
12 EUROPE BRANDED GENERICS MARKET, BY END USER 354
12.1 OVERVIEW 355
12.2 HOSPITALS 358
12.3 CLINICS 358
12.4 HOMECARE 359
12.5 ACADEMIC & RESEARCH INSTITUTES 360
12.6 OTHERS 360
13 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL 361
13.1 OVERVIEW 362
13.2 RETAIL PHARMACIES 365
13.3 HOSPITAL PHARMACIES 366
13.4 DIRECT TENDERS 367
13.5 OTHERS 368
14 EUROPE SHIP REPAIR AND MAINTENANCE SERVICES MARKET, BY REGION 369
14.1 EUROPE 372
14.1.1 GERMANY 398
14.1.2 UNITED KINGDOM 420
14.1.3 ITALY 442
14.1.4 FRANCE 464
14.1.5 SPAIN 485
14.1.6 TURKEY 506
14.1.7 RUSSIA 527
14.1.8 SWITZERLAND 548
14.1.9 NETHERLANDS 569
14.1.10 BELGIUM 590
14.1.11 SWEDEN 610
14.1.12 DENMARK 631
14.1.13 NORWAY 651
14.1.14 FINLAND 671
14.1.15 REST OF EUROPE 691
15 EUROPE BRANDED GENERICS MARKET: COMPANY LANDSCAPE 692
15.1 MANUFACTURER COMPANY SHARE ANALYSIS: EUROPE 692
16 SWOT ANALYSIS 693
17 COMPANY PROFILE 694
17.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. 694
17.1.1 COMPANY SNAPSHOT 694
17.1.2 REVENUE ANALYSIS 695
17.1.3 COMPANY SHARE ANALYSIS 695
17.1.4 PRODUCT PORTFOLIO 696
17.1.5 RECENT DEVELOPMENT 698
17.2 VIATRIS INC. 700
17.2.1 COMPANY SNAPSHOT 700
17.2.2 REVENUE ANALYSIS 701
17.2.3 COMPANY SHARE ANALYSIS 701
17.2.4 PRODUCT PORTFOLIO 702
17.2.5 RECENT DEVELOPMENTS 706
17.3 SANDOZ GROUP AG 708
17.3.1 COMPANY SNAPSHOT 708
17.3.2 REVENUE ANALYSIS 708
17.3.3 COMPANY SHARE ANALYSIS 709
17.3.4 PRODUCT PORTFOLIO 709
17.3.5 RECENT DEVELOPMENTS 712
17.4 DR.REDDY'S LABORATORIES LTD. 714
17.4.1 COMPANY SNAPSHOT 714
17.4.2 REVENUE ANALYSIS 714
17.4.3 COMPANY SHARE ANALYSIS 715
17.4.4 PRODUCT PORTFOLIO 715
17.4.5 RECENT DEVELOPMENTS 721
17.5 SUN PHARMACEUTICAL INDUSTRIES LTD. 723
17.5.1 COMPANY SNAPSHOT 723
17.5.2 REVENUE ANALYSIS 724
17.5.3 COMPANY SHARE ANALYSIS 724
17.5.4 PRODUCT PORTFOLIO 725
17.5.5 RECENT DEVELOPMENTS 730
17.6 ABBOTT 732
17.6.1 COMPANY SNAPSHOT 732
17.6.2 REVENUE ANALYSIS 732
17.6.3 PRODUCT PORTFOLIO 733
17.6.4 RECENT DEVELOPMENTS 734
17.7 ALEMBIC PHARMACEUTICALS LIMITED 735
17.7.1 COMPANY SNAPSHOT 735
17.7.2 REVENUE ANALYSIS 736
17.7.3 PRODUCT PORTFOLIO 736
17.7.4 RECENT DEVELOPMENT 738
17.8 AMNEAL PHARMACEUTICALS LLC. 739
17.8.1 COMPANY SNAPSHOT 739
17.8.2 REVENUE ANALYSIS 739
17.8.3 PRODUCT PORTFOLIO 740
17.8.4 RECENT DEVELOPMENT 741
17.9 ARISTO PHARMACEUTICALS PRIVATE LIMITED 742
17.9.1 COMPANY SNAPSHOT 742
17.9.2 PRODUCT PORTFOLIO 742
17.9.3 RECENT DEVELOPMENT 743
17.10 ASPEN HOLDINGS 744
17.10.1 COMPANY SNAPSHOT 744
17.10.2 REVENUE ANALYSIS 744
17.10.3 PRODUCT PORTFOLIO 745
17.10.4 RECENT DEVELOPMENT 746
17.11 AUROBINDO PHARMA USA (SUBSIDIARY OF AUROBINDO PHARMA LIMITED) 747
17.11.1 COMPANY SNAPSHOT 747
17.11.2 REVENUE ANALYSIS 748
17.11.3 PRODUCT PORTFOLIO 748
17.11.4 RECENT DEVELOPMENTS 751
17.12 BAUSCH HEALTH COMPANIES INC. 754
17.12.1 COMPANY SNAPSHOT 754
17.12.2 REVENUE ANALYSIS 754
17.12.3 PRODUCT PORTFOLIO 755
17.12.4 RECENT DEVELOPMENT 756
17.13 BIOCON. 757
17.13.1 COMPANY SNAPSHOT 757
17.13.2 REVENUE ANALYSIS 757
17.13.3 PRODUCT PORTFOLIO 758
17.13.4 RECENT DEVELOPMENTS 759
17.14 CIPLA 760
17.14.1 COMPANY SNAPSHOT 760
17.14.2 REVENUE ANALYSIS 760
17.14.3 PRODUCT PORTFOLIO 761
17.14.4 RECENT DEVELOPMENTS 764
17.15 EMCURE PHARMACEUTICALS LIMITED 766
17.15.1 COMPANY SNAPSHOT 766
17.15.2 REVENUE ANALYSIS 767
17.15.3 PRODUCT PORTFOLIO 767
17.15.4 RECENT DEVELOPMENTS 770
17.16 ENDO, INC. 772
17.16.1 COMPANY SNAPSHOT 772
17.16.2 REVENUE ANALYSIS 773
17.16.3 PRODUCT PORTFOLIO 773
17.16.4 RECENT DEVELOPMENT 774
17.17 FRESENIUS SE & CO. KGAA 775
17.17.1 COMPANY SNAPSHOT 775
17.17.2 REVENUE ANALYSIS 775
17.17.3 PRODUCT PORTFOLIO 776
17.17.4 RECENT DEVELOPMENT 777
17.18 GLENMARK PHARMACEUTICALS LTD. 778
17.18.1 COMPANY SNAPSHOT 778
17.18.2 REVENUE ANALYSIS 779
17.18.3 PRODUCT PORTFOLIO 779
17.18.4 RECENT DEVELOPMENTS 782
17.19 HIKMA PHARMACEUTICALS PLC 783
17.19.1 COMPANY SNAPSHOT 783
17.19.2 REVENUE ANALYSIS 783
17.19.3 PRODUCT PORTFOLIO 784
17.19.4 RECENT DEVELOPMENTS 785
17.20 INTAS PHARMACEUTICALS LTD. 787
17.20.1 COMPANY SNAPSHOT 787
17.20.2 PRODUCT PORTFOLIO 787
17.20.3 RECENT DEVELOPMENTS 791
17.21 JUBILANT GENERICS LIMITED (SUBSIDIARY OF JUBILANT PHARMA COMPANY) 793
17.21.1 COMPANY SNAPSHOT 793
17.21.2 PRODUCT PORTFOLIO 793
17.21.3 RECENT DEVELOPMENTS 795
17.22 LUPIN 796
17.22.1 COMPANY SNAPSHOT 796
17.22.2 REVENUE ANALYSIS 796
17.22.3 PRODUCT PORTFOLIO 797
17.22.4 RECENT DEVELOPMENTS 801
17.23 MANKIND PHARMA LIMITED 804
17.23.1 COMPANY SNAPSHOT 804
17.23.2 REVENUE ANALYSIS 805
17.23.3 PRODUCT PORTFOLIO 805
17.23.4 RECENT DEVELOPMENTS 809
17.24 NATCO PHARMA LIMITED 810
17.24.1 COMPANY SNAPSHOT 810
17.24.2 REVENUE ANALYSIS 810
17.24.3 PRODUCT PORTFOLIO 811
17.24.4 RECENT DEVELOPMENTS 813
17.25 NEULAND LABORATORIES LTD. 814
17.25.1 COMPANY SNAPSHOT 814
17.25.2 REVENUE ANALYSIS 814
17.25.3 PRODUCT PORTFOLIO 815
17.25.4 RECENT DEVELOPMENT 818
17.26 ORCHIDPHARMA LTD. 819
17.26.1 COMPANY SNAPSHOT 819
17.26.2 REVENUE ANALYSIS 819
17.26.3 PRODUCT PORTFOLIO 820
17.26.4 RECENT DEVELOPMENT 821
17.27 PANACEA BIOTEC 822
17.27.1 COMPANY SNAPSHOT 822
17.27.2 REVENUE ANALYSIS 822
17.27.3 PRODUCT PORTFOLIO 823
17.27.4 RECENT DEVELOPMENT 824
17.28 SAGENT 825
17.28.1 COMPANY SNAPSHOT 825
17.28.2 PRODUCT PORTFOLIO 825
17.28.3 RECENT DEVELOPMENT 826
17.29 STRIDES PHARMA SCIENCE LIMITED. 827
17.29.1 COMPANY SNAPSHOT 827
17.29.2 REVENUE ANALYSIS 827
17.29.3 PRODUCT PORTFOLIO 828
17.29.4 RECENT DEVELOPMENT 831
17.30 TORRENT PHARMACEUTICALS LTD. 832
17.30.1 COMPANY SNAPSHOT 832
17.30.2 REVENUE ANALYSIS 833
17.30.3 PRODUCT PORTFOLIO 833
17.30.4 RECENT DEVELOPMENTS 837
17.31 USV PRIVATE LIMITED. 839
17.31.1 COMPANY SNAPSHOT 839
17.31.2 SERVICE PORTFOLIO 839
17.31.3 RECENT DEVELOPMENT 847
17.32 WOCKHARDT LIMITED 848
17.32.1 COMPANY SNAPSHOT 848
17.32.2 REVENUE ANALYSIS 849
17.32.3 PRODUCT PORTFOLIO 849
17.32.4 RECENT DEVELOPMENT 852
17.33 MCKESSON CORPORATION 853
17.33.1 COMPANY SNAPSHOT 853
17.33.2 REVENUE ANALYSIS 854
17.33.3 PRODUCT PORTFOLIO 855
17.33.4 RECENT DEVELOPMENT 855
17.34 CENCORA, INC. 856
17.34.1 COMPANY SNAPSHOT 856
17.34.2 REVENUE ANALYSIS 857
17.34.3 PRODUCT PORTFOLIO 857
17.34.4 RECENT DEVELOPMENT 858
17.35 CARDINAL HEALTH 859
17.35.1 COMPANY SNAPSHOT 859
17.35.2 REVENUE ANALYSIS 859
17.35.3 PRODUCT PORTFOLIO 860
17.35.4 RECENT DEVELOPMENT 860
17.36 ALVOGEN 861
17.36.1 COMPANY SNAPSHOT 861
17.36.2 SERVICE PORTFOLIO 861
17.36.3 RECENT DEVELOPMENT 861
18 QUESTIONNAIRE 862
19 RELATED REPORTS 865
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security